Lenalidomide also exhibited activity as maintenance therapy in RR DLBCL, especially in ABC subtype for the reason that lenalidomide strongly inhibited NF-kB signaling, key pathogenesis of ABC subtype (45). The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.